As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others
van Assema DME, Lubberink M, Boellaard R, Schuit RC, Windhorst AD, Scheltens P, et al
It is the first membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT), developed at the University of Texas in 2017
Sustained Glutathione Levels: The booster capsules keep glutathione levels steady between treatments for lasting benefits
Blocking MCT1 with BAY8002 can prevent the metabolism of DCs from skewing by tumor-derived glycans and restore their capacity to support effective antitumor T cell responses [77]